CONTESSA: A multinational, multicenter, randomized, phase III registration study of tesetaxel plus a reduced dose of capecitabine in patients (pts) with HER2-, hormone receptor plus (HR plus ) locally advanced or metastatic breast cancer (LA/MBC) who have previously received a taxane Meeting Abstract
| Authors: | O'Shaughnessy, J.; Piccart, M.; Schwartzberg, L. S.; Cortes, J.; Harbeck, N.; Im, S. A.; Rugo, H. S.; Untch, M.; Yardley, D. A.; Bondarenko, I.; Chan, S.; Dieras, V.; Pegram, M. D.; Kroll, S.; O'Connell, J. P.; Vacirca, J.; Wei, T.; Tang, K.; Seidman, A. D. |
| Abstract Title: | CONTESSA: A multinational, multicenter, randomized, phase III registration study of tesetaxel plus a reduced dose of capecitabine in patients (pts) with HER2-, hormone receptor plus (HR plus ) locally advanced or metastatic breast cancer (LA/MBC) who have previously received a taxane |
| Meeting Title: | 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 37 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2019 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2019-05-20 |
| Start Page: | 60s |
| Language: | English |
| ACCESSION: | WOS:000487345803227 |
| DOI: | 10.1200/JCO.2019.37.15_suppl.TPS1107 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: TPS1107 -- Source: Wos |
